rituximab for myasthenia... 投稿者:Milton 投稿日:2026/01/28(Wed) 15:07 No.28484778
THOUSAND OAKS, Calif., Dec. 19, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. Amgen and Allergan are collaborating on 4 oncology biosimilar medicines, two of which have already been accepted by the FDA. David M. Reese, M.D., govt vice president of Analysis and Improvement at Amgen. ABP 798 has been developed as a biosimilar candidate to Rituxan. Rituxan is a CD20-directed cytolytic antibody that has been accepted in lots of areas for, amongst different issues, the therapy of grownup patients alone or together with chemotherapy for non-Hodgkin's lymphoma, together with fludarabine and cyclophosphamide for chronic lymphocytic leukemia, granulomatosis with polyangiitis and microscopic polyangiitis with glucocorticoids. David Nicholson, Ph.D., chief analysis and growth officer at Allergan. The BLA submission consists of analytical, pharmacokinetic and clinical knowledge, in addition to pharmacology and toxicology information generated in two clinical research. The outcomes of those research confirmed no clinically significant variations between ABP 798 and Rituxan.
My webpage - rituximab for myasthenia gravis (https://www.youtube.com/watch?v=l7nhDTewZFE)
|